NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia

NCT01733121 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Tardive Dyskinesia

Interventions

DRUG: NBI-98854
DRUG: NBI-98854
DRUG: Placebo

Sponsor

Neurocrine Biosciences